Vaccine and adjuvant design for emerging viruses mutations, deletions, segments and signaling

Bioengineered Bugs

Volumn 2, Issue 3, 2011, Pages 129-135

  Bowick, Gavin C ^a,b   Mcauley, Alexander J ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Adjuvants; Arenaviruses; Biodefense; Bunyaviruses; Emerging viruses; Filoviruses; Flaviviruses; Viral vaccines

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

ARTICLE; DRUG DESIGN; DRUG SAFETY; GENETIC REASSORTMENT; NONHUMAN; VACCINATION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS PATHOGENESIS; VIRUS RECOMBINANT; VIRUS VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DESIGN; HUMANS; MUTATION; SEQUENCE DELETION; SIGNAL TRANSDUCTION; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

ORTHOBUNYAVIRUS;

EID: 79960268756     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.2.3.15367     Document Type: Article

References (51)

1. Bowick GC, Barrett AD. Comparative pathogenesis and systems biology for biodefense virus vaccine development. J Biomed Biotechnol 2010; 2010:236528.
2. Bowick GC, Fennewald SM, Elsom BL, Aronson JF, Luxon BA, Gorenstein DG, et al. Differential signaling networks induced by mild and lethal hemorrhagic fever virus infections. J Virol 2006; 80:10248-52.
3. Bowick GC, Fennewald SM, Scott EP, Zhang LH, Elsom BL, Aronson JF, et al. Identification of differentially activated cell-signaling networks associated with Pichindé virus pathogenesis by using systems kinomics. J Virol 2007; 81:1923-33.
4. Bowick GC, Fennewald SM, Zhang LH, Yang XB, Aronson JF, Shope RE, et al. Attenuated and lethal variants of Pichindé virus induce differential patterns of NFkappaB activation suggesting a potential target for novel therapeutics. Viral Immunol 2009; 22:457-62.
5. Bowick GC, Spratt HM, Hogg AE, Endsley JJ, Wiktorowicz JE, Kurosky A, et al. Analysis of the differential host cell nuclear proteome induced by attenuated and virulent hemorrhagic arenavirus infection. J Virol 2009; 83:687-700.
6. Bowick GC, Soman KV, Wang H, Aronson JF, Luxon BA, Lomas LO, et al. Proteomic analysis of Pichindé virus infection identifies differential expression of prothymosin-alpha. J Biomed Biotechnol 2010;2010.
7. Djavani M, Crasta OR, Zhang Y, Zapata JC, Sobral B, Lechner MG, et al. Gene expression in primate liver during viral hemorrhagic fever. Virol J 2009; 6:20.
8. Djavani MM, Crasta OR, Zapata JC, Fei Z, Folkerts O, Sobral B, et al. Early blood profiles of virus infection in a monkey model for lassa fever. J Virol 2007; 81:7960-73.
9. Morikawa S, Saijo M, Kurane I. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston). Comp Immunol Microb 2007; 30:391-8.
10. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487-98.
11. Lukashevich IS, Maryankova R, Vladyko AS, Nashkevich N, Koleda S, Djavani M, et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: Different effects on IL-8 and TNFalpha gene expression. J Med Virol 1999; 59:552-60.
12. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, Smith J, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995; 53:405-11.
13. Rossi SL, Ross TM, Evans JD. West Nile virus. Clin Lab Med 2010; 30:47-65.
14. Fennewald SM, Scott EP, Zhang L, Yang X, Aronson JF, Gorenstein DG, et al. Thioaptamer decoy targeting of AP-1 proteins influences cytokine expression and the outcome of arenavirus infections. J Gen Virol 2007; 88:981-90.
15. dos Santos CN, Post PR, Carvalho R, Ferreira II, Rice CM, Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995; 35:35-41.
16. Powell PP, Dixon LK, Parkhouse RM. An IkappaB homolog encoded by African swine fever virus provides a novel mechanism for downregulation of proinflammatory cytokine responses in host macrophages. J Virol 1996; 70:8527-33.
17. Silk RN, Bowick GC, Abrams CC, Dixon LK. African swine fever virus A238L inhibitor of NFkappaB and of calcineurin phosphatase is imported actively into the nucleus and exported by a CRM1- mediated pathway. J Gen Virol 2007; 88:411-9.
18. Neilan JG, Lu Z, Kutish GF, Zsak L, Lewis TL, Rock DL. A conserved African swine fever virus IkappaB homolog, 5EL, is nonessential for growth in vitro and virulence in domestic swine. Virology 1997; 235:377-85.
19. Afonso CL, Piccone ME, Zaffuto KM, Neilan J, Kutish GF, Lu Z, et al. African swine fever virus multigene family 360 and 530 genes affect host interferon response. J Virol 2004; 78:1858-64.
20. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007; 196:404-12.
21. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 2008; 26:6894-900.
22. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:2.
23. Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol 2008; 82:2699-704.
24. Hartman AL, Ling L, Nichol ST, Hibberd ML. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 2008; 82:5348-58.
25. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005; 79:13934-42.
26. Lukashevich IS, Zapata JC, Goicochea M, Carrion R, Patterson JL, Brasky K, et al. Safety and efficacy of ML29 reassortant lassa fever vaccine in non-human primates. Int J Infect Dis 2008; 12:252-3.
27. Zhang L, Marriott KA, Harnish DG, Aronson JF. Reassortant analysis of guinea pig virulence of pichinde virus variants. Virology 2001; 290:30-8.
28. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11:438-44.
29. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196:430-7.
30. Boisgerault F, Moron G, Leclerc C. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 2002; 1:101-9.
31. Neumann G, Watanabe T, Kawaoka Y. Plasmiddriven formation of influenza virus-like particles. J Virol 2000; 74:547-51.
32. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76:4855-65.
33. Patch JR, Crameri G, Wang LF, Eaton BT, Broder CC. Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J 2007; 4:1.
34. Landry N, Ward BJ, Trepanier S, Montomoli E, Dargis M, Lapini G, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:15559.
35. Shi W, Liu J, Huang Y, Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 2001; 75:10139-48.
36. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000; 74:4933-7.
37. Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. Phosphoinositide-3-kinase-Akt pathway controls cellular entry of Ebola virus. Plos Pathogens 2008; 4:1000141.
38. Huang H, Xiao S, Qin J, Jiang Y, Yang S, Li T, et al. Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. Arch Virol 2011; 156:753-8.
39. Cann AJ, Stanway G, Hughes PJ, Minor PD, Evans DM, Schild GC, et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res 1984; 12:7787-92.
40. Barrett AD, Teuwen DE. Yellow fever vaccine-how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol 2009; 21:308-13.
41. Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, Watts DM, et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2010; 28:3827-40.
42. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-6.
43. Sasaki MG, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003; 21:4545-9.
44. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Metaanalysis: the adjuvant role of granulocyte macrophage- colony stimulating factor on immunological response to hepatitis B virus vaccine in endstage renal disease. Aliment Pharmacol Ther 2006; 24:789-96.
45. Hogg AE, Bowick GC, Herzog NK, Cloyd MW, Endsley JJ. Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1. J Leukoc Biol 2009; 86:1191-203.
46. Lee AW, Sharp ER, O'Mahony A, Rosenberg MG, Israelski DM, Nolan GP, et al. Single-cell, phosphoepitope- specific analysis demonstrates cell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J Virol 2008; 82:3702-12.
47. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75:1205-10.
48. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-25.
49. Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J 2010; 7:279.
50. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, et al. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 2010; 84:9947-56.
51. Pai Kasturi S, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-7.